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C
ardiac catheterisation and angiography uses ionising
radiation and therefore produces a radiation dose to the
patient and to the operating staff. The dose to the patient
can be measured using thermoluminescent dosemeters placed
on the skin or by using a large-area detector attached to the x
ray tube to measure the dose–area product (DAP) for the
incident x ray beam (DAP meter). The DAP is particularly useful
for assessing and comparing the radiation dose from screening
procedures. It provides a more useful indication of the overall
patient exposure than measurement of surface dose at
particular locations. The dose measurement is used either as a
surrogate for radiation risk or as a step in actually estimating
the risk. Published factors allow conversion of the DAP to
effective dose, a derived quantity in which doses to different
organs or tissues are weighted according to their radio-
sensitivity and summed to give a risk-related dose quantity.1–5
UK legislation does not give dose limits for patients under-
going medical diagnostic exposures, but requires adherence to
the ‘‘as low as reasonably practicable’’ principle, and compar-
ison of doses with diagnostic reference levels for common
procedures. Published data for patient exposure, absorbed dose,
effective dose and risk of malignancy from the different specific
diagnostic cardiac catheterisation procedures are incomplete,
and there are no national diagnostic reference levels for
individual procedures.
We undertook this study with the aim of establishing local
patient doses for six different diagnostic cardiac catheterisation
procedures by looking at screening times and DAP results, and
then establishing the effective dose. From these values, we
estimated the patient risk in each specific procedure group.
METHOD
We prospectively collected data on 4398 diagnostic cardiac
examinations carried out in a regional cardiac catheter
laboratory over a period of 3 years. We did not include patients
who had coronary angiography and went on to have
revascularisation. The patients’ demographic details and the
examination details were recorded (including screening time,
number of acquisitions and number of cine frames).
The x ray equipment used was a digital Philips Polydiagnost
C2 single-plane image-intensifier system (installed in 1992),
which has an automatic control of x ray exposure parameters.
The average tube potential was 80 kVp (kilovoltage peak) and
the total filtration was 4 mm aluminium (equivalent thickness
of aluminium). The tube potential and the filtration were kept
constant throughout all procedures. A diamentor (PTW-
Physikaliche Technische Werkstaetten, Freiberg) was used to
measure the DAP. The recorded DAP values were corrected to a
standard patient size. Effective dose measured in milliSieverts
was calculated from the DAP reading using conversion factors
for the various projections corresponding to a filtration of 4 mm
aluminium and a mean tube kilovoltage of 80 kV as described
previously.1 5 The proportion of total DAP assigned to each
projection was estimated for each of the six diagnostic groups
in the study, to derive a conversion factor for each examination
group (0.23 mSv/Gy cm2 for right anterior oblique views and
0.205 mSv/Gy cm2 for left anterior oblique views).
We estimated the risk of malignancy for each specific
examination from the effective dose values. Published reports
indicate an estimate of 2.5% per Sievert (2.561022/Sv or 1 in
40 000/mSv) additional lifetime risk of fatal cancer for a
population between the ages of 40 and 60 years, and this figure
has been used for comparative purposes here. Additional details
and the methods of statistical analysis are available in a
supplementary report at http://heart.bmj.com/supplemental.
RESULTS
The descriptions of the projections used, conversion factors and
demographic details of the patients studied are available in the
supplementary report. Table 1 summarises the screening time,
DAP, effective dose and estimated risk of malignancy for the
different groups. Diagnostic group 1 had the lowest values of
DAP and effective dose compared with the other diagnostic
groups, with the lowest additional lifetime risk (0.011%) of
malignancy (LROM). The sequential increase in LROM from
one group to another was statistically significant except for
groups 3 and 4, which had equivalent risk.
DISCUSSION
The potential harmful effects of radiation are documented
along with permitted recommended safe dose limits to staff
(International Commission on Radiological Protection). Two
types of radiation effects may occur: deterministic (skin
erythema and ulceration) and stochastic effects. The risk of
long-term stochastic effects (eg, cancer, leukaemia) is usually
assessed by effective dose, which makes some allowance for the
properties of the radiation concerned and for non-uniform
distribution of radiation over the body. We did not observe any
deterministic effect in the current patient population. We did
not perform long-term follow-up of these patients to evaluate
the appearance of stochastic effects; the estimated frequency of
malignancy would require a long-term follow-up of a cohort
larger than ours to prospectively validate our estimates.
The DAP measurements have been widely used in previous
studies either as a means of comparison of radiation dose or as
a step for estimation of risk. Our results on the DAP
measurements and effective dose are comparable to previous
studies. However, this is the first study to describe in detail the
hypothetical additional LROM in patients undergoing different
radiological cardiac diagnostic procedures. This study also
provides diagnostic reference levels as recommended by the
Abbreviations: DAP, dose–area product; LROM, lifetime risk of
malignancy
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International Commission on Radiation Protection (ICRP 60),
as directed in Europe by Council Directive 97/43/Euratom and
as implemented in the UK by the Ionising Radiation (Medical
Exposure) Regulations 2000.
In a previous report, the mortality associated with cardiac
catheterisation and coronary angiography was 0.11%. The
incidence of total major complications was 1.7%. Living in
Cornwall (UK) has an additional radiation of 7 mSv/year and a
flight to the US has an additional radiation dose of 40–50 mSv.
The typical effective dose for a chest x ray (PA) is 0.02 mSv and
for angiography is 10 mSv. Magnetic resonance coronary
angiography does not involve radiation, and nuclear medicine
involves 8–20 mSv of radiation.
The risks associated with coronary heart disease itself and the
procedure of coronary angiography are relatively high com-
pared with the hypothetical additional lifetime risk of
malignancy in patients undergoing different radiological
cardiac diagnostic procedures. Nevertheless, the additional
LROM should not be ignored, particularly for younger patients,
especially given the high numbers of cardiac procedures
performed worldwide. In addition, the information provided
allows informed consent for asymptomatic patients undergoing
repeat coronary catheterisation as part of a clinical trial rather
than for a specific clinical indication.
The radiation dose to the patient can be minimised by
opening the iris on the television camera, allowing a lower
increase in beam intensity and also by using flat panel detectors
which have more sophisticated controls. To minimise scatter,
an air gap between the patient and the detector can be used. In
addition, the need for left ventriculography can be questioned if
the relevant information can be acquired by non-invasive
means.
More complex cardiac radiological procedures are associated
with higher radiation doses, thereby greatly increasing the
lifetime risk of malignancy. Every additional procedure must
always be justified by a positive balance of benefit over risk for
each patient. Stochastic risks of radiation by and large should
not greatly affect this judgement, given that non-radiation risks
are an order of magnitude higher.
Additional details and statistical analysis methods are
available at http://heart.bmj.com/supplemental
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Kunadian Vijayalakshmi, Dee Kelly, David Williams, Robert Wright,
Michael J Stewart, James A Hall, Andrew Sutton, Adrian Davies, John
Haywood, Mark A de Belder, Departments of Cardiology and Medical
Physics, The James Cook University Hospital, Middlesbrough, UK
Claire-Louise Chapple, Regional Medical Physics Department, Newcastle
General Hospital, Newcastle upon Tyne, UK
Competing interests: None declared.
Correspondence to: Dr M A de Belder, Department of Cardiology, The
James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW,
UK; mark.debelder@stees.nhs.uk
Accepted 7 August 2006
REFERENCES
1 Hart D, Jones D, Wall B. Estimation of effective dose in diagnostic radiology from
the entrance surface dose and dose-area product measurements. Radiat Prot
Board NRPB 1994;R262:1–57.
2 Broadhead D, Chapple C, Faulkner K, et al. The impact of cardiology on the
collective effective dose in the North of England. Br J Radiol 1997;70:492–7.
3 Rassow S. From the entrance dose to the calculation of organ doses. Radiat Prot
Dosim 1998;80:327–9.
4 Le Heron J. Estimation of effective dose to the patient during medical x-ray
estimations from measurements of the dose-area product. Phys Med Biol
1992;37:2117–26.
5 Leung K, Martin C. Effective dose for coronary angiography. Br J Radiol
1996;69:426–31.
Table 1 Screening time (s), dose–area product (Gy cm2), effective dose (mSv) and estimated risk (%) of malignancy for diagnostic
cardiac imaging
Groups Number Screening time DAP (Gy cm2) ED (mSv) Risk (%)
Additional risk of
cancer
A.COR 464 240.7 (333.9, 114) 20.1 (17.7, 15.6) 4.4 0.011 1 in 9000
A.LVC 3288 199 (242, 120) 21.7 (11.9, 19.1) 4.8 0.012 1 in 8000
RHLVC 207 529.9 (398, 420) 32.1 (20.3, 27.4) 7.0 0.018 1 in 6000
A.LAC 194 414.6 (412, 279) 33 (18, 29.4) 7.4 0.018 1 in 6000
A.CAB 175 697 (486, 558) 40.3 (18, 37.7) 8.9 0.022 1 in 5000
A.CAC 70 815.3 (487.5, 732) 51.4 (22.6, 46.8) 11.5 0.029 1 in 3000
A.CAB, ventriculography, coronaries and graft studies; A.CAC, aortogram, coronaries and graft study; A.COR, coronaries only; A.LAC, aortogram and coronaries;
A.LVC, left ventriculography (LV) and coronaries; DAP, dose–area product; ED, effective dose; RHLVC, right heart catheterisation with A.LVC.
Values are expressed as mean (SD, median).
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